3-rx.comCustomer Support
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics

\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>

Join our Mailing List


You are here : 3-RX.com > Home > Drug News - Flu - Immunology -

Fungus-fighting drug may make mild flu meaner

Drug News • • Flu • • ImmunologyNov 22, 13

Fungus-fighting drug may make mild flu meaner

Mice given a drug commonly used in patients to fight systemic fungal infections more often succumb to what would otherwise be a mild case of the flu. The evidence reported in the Cell Press journal Cell Reports on November 21st shows that the drug called Amphotericin B, which has an estimated $330 million in sales around the world each year, can render a protein important for antiviral defense ineffective in both cells and mice.

The findings suggest that patients receiving the antifungal therapy may be functionally immunocompromised and more vulnerable to influenza and other viral infections, the researchers said.

“Many critically ill cancer and bone marrow transplant patients are treated with Amphotericin B-based therapies each year,” said Abraham Brass of the University of Massachusetts Medical School (UMMS). “Given these results in cells and mice, it may be worthwhile to consider that patients receiving, or who may receive, Amphotericin B-based therapies be appropriately vaccinated against influenza virus. Also, clinical consideration may be given to close monitoring of patients receiving Amphotericin B-based therapies for any symptoms suggestive of flu so that they might be considered for the early administration of an antiflu therapy.”

The researchers showed that Amphotericin-B prevents the antiviral protein in cells known as IFITM3 from fending off influenza A virus.

“When we treated lung cancer cells with the antifungal drug, we saw the antiviral protection from IFITM3 pretty much disappear,” explained Christopher Chin, co-first author, also from UMMS.

When researchers in Paul Kellam’s group at the Wellcome Trust Sanger Institute exposed mice treated with Amphotericin-B to influenza A virus, the animals became very ill and lost more than 25 percent of their body weight. Those symptoms looked very similar to those in animals completely lacking the protective IFITM3 protein. Mice that had not been treated with Amphotericin-B experienced only a moderate illness and recovered fully, as expected. In effect, treatment with Amphotericin-B converted a mild illness for the mice into a life-threatening one.

“Sometimes a very useful drug can have unforeseen effects, and the more we can learn about such things, the better care we can provide,” Brass said.

The new study should prompt further clinical research. For instance, he added, studies could be designed to monitor both the number and the severity of flu infections in patients receiving Amphotericin B-based therapies.


Cell Reports, Lin et al.: “Amphotericin B Increases Influenza A Virus Infection by Preventing IFITM3-mediated Restriction.”


Mary Beth O’Leary
.(JavaScript must be enabled to view this email address)
Cell Press

Print Version
comments powered by Disqus

  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  UGA ecologist finds another cause of antibiotic resistance
  New drug for neuroblastoma shows promise in phase I study
  Drug prevents passage of HBV during pregnancy
  Designing better medical implants
  Baclofen shows promise in patients with alcohol-induced liver disease
  Findings point to an ‘off switch’ for drug resistance in cancer
  Stopping statins may benefit terminally ill patients
  Scientists discover potential new target for cancer immunotherapy
  Cholesterol drug users may use pills as a license to overeat
  Tamiflu-resistant influenza: Parsing the genome for the culprits
  Pfizer lung cancer drug beats chemo for previously untreated patients


Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site